-
- 1800 2010
- EN
-1366x0.jpg)
News
Array
(
[0] => stdClass Object
(
[id] => 1139
[id_crawler] =>
[category_product] => NULL
[thumbnail] => hoi-nghi-acp-2023.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 1
[displayed_time] => 2023-10-03
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2023-10-03 15:50:49
[updated_time] => 2024-08-16 13:39:13
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => gentis-the-main-sponsor-of-the-acp-2023-annual-scientific-conference
[title] => GENTIS - The Main Sponsor of the ACP 2023 Annual Scientific Conference
[description] => Recently, the Phuong Chau Medical Corporation organized the 2023 Annual Scientific Conference (ACP) with the theme "Enhancing Excellent Medical Experiences for the Community" at the CB Diamond Palace Convention Center (Can Tho City). GENTIS proudly participated as the Main Sponsor and showcased a product exhibition booth.
[content] => 
GENTIS washonored to be the main sponsor of the ACP 2023 Annual Scientific Conference
The ACP 2023 Annual Scientific Conference is a significant event organized by the Phuong Chau Medical Corporation, attracting over 1,000 delegates including leading experts, healthcare professionals, and staff from hospitals specializing in Obstetrics and Gynecology, Infertility, Pediatrics and Neonatology, General Medicine, Quality Management - Hospital Management, and Nursing from southern provinces and cities. This event provides an opportunity for professionals to interact, learn, and exchange knowledge and experience in the medical field.
This year's conference featured 48 reports on the most current topics in Obstetrics and Gynecology, Pediatrics, Infertility, General Medicine, Nursing, and Quality Management - Hospital Management. The reports were presented by senior hospital management leaders from the Phuong Chau Medical Corporation and leading experts from hospitals in the southern region.
GENTIS's product introduction booth attracted the attention of many delegates
A highlight of GENTIS's participation in the ACP 2023 Annual Scientific Conference was its product exhibition booth. Here, doctors and experts had the opportunity to explore the most comprehensive and modern genetic testing ecosystem and receive valuable gifts of gratitude. Leading experts highly praised GENTIS's tests, especially the NIPT, PGT Max 1 tests, etc,...
Many customers visited GENTIS's booth to receive gifts
Through our service introduction activities at the ACP 2023 Annual Scientific Conference, GENTIS hopes to continue partnering with doctors and experts in bringing genetic tests closer to the Vietnamese population.
[content_more] =>
[meta_title] => GENTIS - The Main Sponsor of the ACP 2023 Annual Scientific Conference
[meta_description] => Recently, the Phuong Chau Medical Corporation organized the 2023 Annual Scientific Conference (ACP) with the theme "Enhancing Excellent Medical Experiences for the Community" at the CB Diamond Palace Convention Center (Can Tho City). GENTIS proudly partic
[meta_keyword] =>
[thumbnail_alt] =>
[post_id] => 1139
[category_id] => 4
)
[1] => stdClass Object
(
[id] => 1136
[id_crawler] =>
[category_product] => NULL
[thumbnail] => ht-sk_2023/hn_di_truyen_thai_binh/wweb_chinh.png
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 1
[displayed_time] => 2023-10-03
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2023-10-03 08:24:59
[updated_time] => 2024-08-15 16:28:38
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => GENTIS is honored to be the Main Sponsor of the 2023 National Scientific Conference of the Vietnam Medical Genetics Association.
[title] => GENTIS is honored to be the Main Sponsor of the 2023 National Scientific Conference of the Vietnam Medical Genetics Association.
[description] => The 2023 National Scientific Conference is an annual event organized by the Vietnam Medical Genetics Association, which will take place on October 6-7, 2023 at Thai Binh University of Medicine and Pharmacy. This year, GENTIS is honored to accompany the conference as the Main Sponsor.
[content] => This is an important activity of the Vietnam Medical Genetics Association, held once a year. This year's conference has the theme "Genetic Diagnosis, Prenatal and Newborn Screening", and is expected to attract more than 500 delegates, including doctors, experts and medical professionals in the field of genetics, obstetrics and gynecology, assisted reproduction, neonatal pediatrics and related specialties nationwide.
The conference’s agenda:
I. Continuing Medical Education Course: October 6, 2023: 2:00 PM - 3:30 PM
Topic: Clinical Cancer Genetics
II. Executive Board Meeting: October 6, 2023: 6:00 PM
- Gala dinner: 7:00 PM, October 6, 2023.
- LOCATION: Thai Binh Dream Hotel, No. 355 Ly Bon - 241 Hai Ba Trung, De Tham Ward, Thai Binh City
III. Official Conference on October 7, 2023: 8:15 AM - 5:15 PM
- Plenary Session: 8:30 AM - 10:30 AM: Hall 1
- 3 thematic Sessions: 40 scientific reports
+ Session 1: Cancer Genetics
+ Session 2: Cardiovascular and hematologic genetics, rare diseases
+ Session 3: Prenatal screening and diagnosis
- 30 poster presentations on medical genetics.
When attending this conference, doctors/partners should not miss the main activities of GENTIS:
- Exhibition booth, introducing products with many advanced gene testing documents, along with many valuable gifts for doctors and delegates.
- Booth No. 1, Thai Binh University of Medicine and Pharmacy, Thai Binh City
- GENTIS representative - Nguyen Thi Huyen, MSc. MD. - Genetic Analysis Services Joint Stock Company (GENTIS) will present a scientific report on Newborn Screening for Metabolic Disorders.
At the same time, GENTIS also provides information on tests for the report topics on genetic diagnosis, prenatal screening and newborn screening.
We look forward to welcoming you, delegates and doctors!
Recurrent Pregnancy Loss: A Comprehensive Overview
Recurrent pregnancy loss is characterized by the loss of three or more consecutive pregnancies prior to the 20th week of gestation (Ford, 2009), excluding ectopic, molar, and biochemical pregnancies. This condition affects approximately 1-2% of women of reproductive age and remains a significant clinical challenge (Stephenson, 1996).
Nevertheless, when recurrent pregnancy loss is defined as the loss of two or more consecutive pregnancies (ACOG, 2013), the incidence rises to 5%. The risk of subsequent pregnancy loss increases to 24% after two miscarriages, 30% after three miscarriages, and up to 40% after four consecutive miscarriages (Regan, 1989).
Etiologies of recurrent pregnancy loss included:
- Anatomical uterine abnormalities, infections
- Endocrine and immunological disorders
- Thrombophilia
- Genetic abnormalities
- Environmental factors and causes unknown
Thrombophilia, a heterogeneous group of inherited or acquired thrombophilic disorders, has emerged as a significant risk factor for recurrent pregnancy loss.
Classification of Thrombophilia
Thrombophilia is a heterogeneous group of disorders characterized by an increased tendency of blood to clot. Both inherited and acquired thrombophilic states are prevalent. Approximately 15% of the Caucasian population carries a genetic mutation associated with a hypercoagulable state.
Classification of thrombophilia includes:
Inherited thrombophilia: Characterized by genetic mutations such as Factor V Leiden (FVL), prothrombin factor II G20210A gene mutation (FII), methylenetetrahydrofolate reductase mutation (MTHFR) leading to hyperhomocysteinemia, and plasminogen activator inhibitor-1 (PAI-1) gene mutations.
Acquired thrombophilia: Including antiphospholipid syndrome (APS), protein S deficiency, and protein C deficiency.
Combined thrombophilia: A combination of inherited and acquired thrombophilic states, such as methylenetetrahydrofolate reductase gene (MTHFR) mutation in conjunction with folate and vitamin B12 deficiency.
Thrombophilia and Recurrent Pregnancy Loss
Recent research has focused on systematic reviews investigating the association between inherited thrombophilia and recurrent pregnancy loss, the role of thrombophilic gene polymorphisms, the efficacy of low-molecular-weight heparin, and the specific contributions of prothrombin G20210A mutation, Factor V Leiden mutation, and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms to recurrent miscarriage.
Women with a history of recurrent pregnancy loss should undergo a comprehensive preconception evaluation 3-5 months prior to attempting conception. This evaluation should include a thorough medical history, physical examination, and appropriate laboratory investigations to identify and address underlying factors contributing to infertility or recurrent pregnancy loss.
Thrombophilia Testing at GENTIS
|
Thrombophilia |
Thrombophilia + |
|
Detected 6 variables on 4 genes: - MTHFR: C677T, A1298C - F2: G20210A (Prothrombin FII) - F5: G1691A (FV Leiden); A4070G (FVR2) - PAI-1: Separin PAI-1 4G/5G
|
Detected 13 variables on 11 genes - MTHFR: C677T, A1298C - F2: G20210A (Prothrombin FII) - F5: G1691A (FV Leiden); A4070G (FVR2) - PAI-1: Separin PAI-1 4G/5G - F7: G10967A (Arg353Gln) - F13A1 (FXIII): G103T (Val34Leu) - ITGA2: C807T (Phe224Phe) - ITGB3: T1565C (Leu33Pro) - FGB (BF): -455G>A - MTRR: A66G (Ile22Met) - TFPI: C536T (Pro179Gln) |
Sample required: 2ml of whole blood
Method: Genetic sequencing
Turnaround time: 5 days
Sensitivity: 100%
Specificity: 100%
Sources: hosrem.org.vn, vinmec.com
REFERENCES
- ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstetrics & Gynecology. 2018; 132(1): e18-e34.
- Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012; 98 (5): 1103-1111.
- Ford HB & Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Reviews in obstetrics & gynecology. 2009; 2(2): 76–83.
- No, Green-top Guideline. The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage, April 2011.
- Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol. 2012; 120(6): 1514-1521.
- Rey E et al. Thrombophilic disorders and fetal loss: a meta-analysis, Lancet. 2003; 361(9361): 901-908.
- The ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss, Human Reproduction Open. 2018; (2).
3 types of PGTest tests commonly used today
PGT-A (Preimplantation Genetic Screening for Aneuploidy)
PGT-A is a preimplantation genetic analysis test that helps detect abnormalities in the number of chromosomes in the embryo. Chromosomes are genetic materials containing DNA. The number of each type of human’s chromosome is 2. When the number of chromosomes changes, it can impede the embryo from developing, consequently failing to be implanted in the uterus, or can cause Down, Turner, Klinefelter Syndrome,...
PGT-SR (Preimplantation Genetic testing for structural chromosomal rearrangements)
PGT-SR is an evaluation test for abnormalities caused by chromosomal restructuring. The PGT-SR test can detect chromosomal abnormalities caused by non-reciprocal translocation, Robertsonian translocation and inversions.
PGT-M (Preimplantation genetic testing for monogenic/single gene defects)
PGT-M is a preimplantation genetic analysis test that detects diseases due to single-gene disorders.
In which circumstance should the PGTEst be applied?
PGT-A
PGT-A is a preimplantation genetic test aiming at identifying aneuploidy abnormalities, which can be deployed to screen aneuploidy types relating to any chromosome. PGT-A should be commonly indicated to:
- Expectant mothers aged > 37 years old.
- Multiple IVF failures or successive miscarriages.
- Family history of children born with quantitative abnormalities of chromosomes.
- The husband is diagnosed with severe infertility (AZF deletion).
.png)
PGT-SR
PGT-SR is often applied to couples with chromosomal structural abnormalities such as chromosomal non-reciprocal translocation, chromosomal deletion or duplication.
In case one or both parents have syndromes related to chromosomal structural abnormalities such as: Angelman, Cri du chat, DiGeorge, Langer – Giedion, Miller – Dieker, Prader – Willi, Smith – Magenis, Williams – Beuren, Wolf – Hirschhorn...
PGT-M
Spouses carry genetic mutations that cause diseases: Thalassemia, Myeloid atrophy, cystic fibrosis,...
The wife carries the sex chromosome X-linked gene mutation (Hemophilia, Duchenne muscular dystrophy...)
PGT-M is a diagnostic test for monogenic diseases that is often recommended for cases such as parent or both parents carrying monogenic genetic mutations such as chromosomal disorders, congenital hemolytic disease Thalassemia, Duchenne muscular dystrophy, congenital adrenal hyperplasia, etc.
Reasons that couples should take the PGTest test
Increase in the success rate per transfer attempt: Choosing embryos that do not have an abnormal number of chromosomes can increase the pregnancy rate after embryo transfer.
Reduction in miscarriage rate: In the general population, 25% of all clinical pregnancies end in miscarriage. The risk of miscarriage will be reduced if the embryo does not have an abnormal number of chromosomes (euploids) transferred.
Reduction in the risk of multiple pregnancies: Patients can confidently transfer an embryo that has been tested for chromosomes and not have an abnormal number of embryos instead of transferring multiple embryos that have not been tested for chromosomes, which reduces the risk of multiple pregnancies.
Increase the likelihood of having a healthy baby: Some pregnancies with aneuploid fetus can lead to the baby being affected in relation to chromosomal syndromes (e.g. Down syndrome).
Less time and resources needed: The time and resources required to achieve a pregnancy are reduced.
GENTIS - The agency that performs accurate and reputable PGTest testing
GENTIS with more than 13 years of operation in the field of obstetric-assisted testing is considered capable of performing PGTest testing techniques accurately and professionally.
GENTIS testing center is strongly invested in facilities, modern equipment systems, imported from famous technology companies in the world. The entire operation process of GENTIS Testing Center is accredited by ISO 9001:2015 and ISO 15189:2012 standards.
.jpg)
At GENTIS, we gather a team of highly specialized experts, doctors, and technicians with many years of experience in the field of assisted reproduction and especially in the technique of performing PGTest tests.
With the desire to improve the health quality of Vietnamese people, GENTIS always tries day by day, to actively improve service quality, and diversify reproductive support products to serve the community. GENTIS hopes to bring more good news to infertile couples looking for children.
The scientific paper was carried out by Pham Dinh Minh, PhD., Nguyen Thi Kieu Oanh, MSc., Nguyen Thi Huyen, MSc. MD (GENTIS Genetic Analysis Services JSC), and Dang Thi Nga, MSc.MD. (University of Public Health). The research was conducted from January 2023 to May 2023 at the GENTIS Testing Center.
After a three-month approval process, the paper was published in the Vietnam Medical Journal on August 30, 2023. This prestigious journal is highly regarded and widely read both within and outside the medical community.
Congenital metabolic disorders are rare genetic conditions in children caused by deficiencies in receptors, enzymes, transport proteins, or co-factors in the metabolism of amino acids, fatty acids, and organic acids. This leads to abnormal changes in the synthesis or degradation pathways of substances in the body, resulting in toxic products that cause cytotoxicity and impair organs’ functions.
Metabolic disorders often go undetected due to the lack of clear symptoms in the early stages of a newborn's development. Consequently, when clinical symptoms appear, it is often too late, leading to mild to severe neurological dysfunctions, developmental delays, and even death.
Therefore, newborn screening for metabolic disorders is crucial for early diagnosis, timely treatment, improving quality of life for patients, and reducing burdens on families. Advances in mass spectrometry technology, particularly tandem mass spectrometry (MSMS), have made screening more affordable, sensitive, and specific. The Neobase 2 kit running on the XEVO TQD system based on the MSMS technique uses dried blood spots from heel pricks to screen for multiple metabolic disorders quickly and accurately.
The XEVO TQD liquid chromatography-mass spectrometry system by Waters is IVD-certified, offering high reliability, sensitivity in monitoring MRM transitions, rapid switch rates, and cost efficiency for laboratories. The NeoBase 2 Non-derivatized MSMS kit by Perkin Elmer can screen for 77 different congenital metabolic disorders. Before integrating the kit into screening for metabolic disorders on the XEVO TQD, method validation is required. Thus, aim of the study is: “Applying CLSI's NBS04 guideline in validating the method for quantifying some amino acids and acylcarnitines on dried heel blood samples using the NeoBase 2 kit on the XEVO TQD machine.”
The XEVO TQD liquid chromatography-mass spectrometry system by Waters is IVD-certified, offering high reliability
The report by GENTIS and the University of Public Health demonstrated that the MSMS method for analyzing amino acids and acylcarnitines using the Neobase-2 kit on the Xevo TQD system provides acceptable linearity, precision, and accuracy, ensuring reliability for neonatal screening services.
“A Verification method in Newborns Screening of Metabolic Disorders by the NEOBASE 2 MSMS KIT using XEVO TQD” is a significant scientific achievement contributed by the R&D team at GENTIS and experts at the University of Public Health to the national medical field. Particularly, the MSMS method for screening congenital metabolic disorders has proven accurate and reliable under the practical conditions of the GENTIS Testing Center, supporting clinical practices in screening various congenital metabolic disorders.
Sharing about this achievement, Pham Dinh Minh, PhD. said: “GENTIS prioritizes ensuring the highest quality of tests. Therefore, validating methods before introducing new equipment is indispensable.”
With the desire to contribute more to the development of the national medical field, GENTIS will strive to conduct more research, bringing quality and meaningful scientific papers in the future.
Read the full scientific paper published in the Vietnam Medical Journal here:
https://tapchiyhocvietnam.vn/index.php/vmj/article/view/6528/5834
The program was organized with the aim of providing and conveying accurate medical information to the audience and to directly connect with the audience, especially the partners and customers. It also seeks to pursue the promotion of health protection and care awareness among the people. The talk show was done in the form of an online consultation on the official GENTIS Fanpage and the talk show was later aired on other online channels like YouTube etc,...
The Talk show “Genetic Counseling – Discussion with Experts” about “Guidance of Newborn Screening for Hemoglobinopathy Testing and Result Analysis.” with the presentation of Tran Thi Mai Chi, MD.PhD. and Pham Dinh Minh, PhD.
In the view of the WHO, approximately 8 million children are born annually with some birth defects. Of them, hemoglobinopathies are the most widespread type of genetic diseases across the world, although 7% of the population has the gene of the disease.
Understanding the importance of diagnosing and screening for hemoglobinopathies, GENTIS was honored to have two leading experts in pediatrics and genetic testing join this genetic counseling and expert discussion program:
- Tran Thi Chi Mai, MD. PhD.: Head of the Department of Biochemistry, Vietnam National Hospital of Paediatrics and Head of the Department of Medical Technology, Hanoi Medical University
- Pham Dinh Minh, PhD.: Director of R&D center , GENTIS
During the show, Dr. Mai has provided useful insights about hemoglobinopathies and newborn screening of these disorders. She stressed that newborn screening for hemoglobinopathies is very important for identification of affected infants. These are acquired disorders that are inherited and result in either the abnormal synthesis or abnormal structure of the hemoglobin chain.
During the show, Tran Thi Chi Mai, MD., PhD. has provided useful insights about hemoglobinopathies and newborn screening for these disorders.
Screening facilitates early detection, enabling doctors to implement appropriate diagnostic and treatment strategies. This helps minimize complications and improves the quality of life for affected children. For children diagnosed with hemoglobinopathies, doctors would provide genetic counseling to families to assist with family planning for future pregnancies.
Furthermore, newborn screening for hemoglobinopathy ] helps identify individuals who may be carriers of the disease gene. Genetic testing for these individuals empowers them to make informed decisions about marriage and family planning to prevent having children with the condition.
Answering a question from Dr. Linh about the need for gene analysis after a positive newborn screening result, Dr. Mai explained, "All cases with positive screening results require genotype analysis for confirmation. For cases where the disease is detected after screening and gene analysis, parents are recommended to undergo genetic testing as well."
Hemoglobinopathies are autosomal recessive disorders, so when a child is diagnosed, it means both parents are carriers. Therefore, genetic testing for parents is crucial for family planning purposes, offering hope for healthy children in subsequent pregnancies."
Pham Dinh Minh, PhD. shared the outstanding advantages of the newborn screening test for hemoglobinopathy at GENTIS.
Dr. Pham Dinh Minh highlighted, "GENTIS specializes in advanced testing, and we strive to provide our partners and customers with the highest test quality, giving doctors and families greater peace of mind in diagnosis and treatment. In addition to newborn screening for hemoglobinopathy, GENTIS offers a comprehensive genetic testing ecosystem to support the birth of healthy babies, including PGT-M for Thalassemia, Hemophilia, and more."
Dr. Minh emphasized that technology is paramount in determining test quality and accuracy. GENTIS has invested in a High-Performance Liquid Chromatography (HPLC) system from Bio-rad, USA, which offers 100% sensitivity for several major variants and ensures high accuracy. This enables GENTIS to meet testing demands in terms of turnaround time, cost-effectiveness, and delivering optimal value to doctors and clients.
Beyond quality, GENTIS prioritizes post-test counseling. For complex cases, GENTIS provides support from leading genetics and heredity experts, such as Tran Thi Chi Mai, MD. PhD., to address concerns and provide in-depth consultations.
GENTIS hopes that the valuable information shared by the two experts on "Guidelines for Testing and Analyzing Results of Newborn Screening for Hemoglobinopathy" will address the questions of doctors and the audience. GENTIS is committed to organizing more meaningful programs to deliver beneficial knowledge to medical professionals and valued customers.
The ISO 15189:2012 accreditation certificate is assessed and issued by the Bureau of Accreditation (BoA) under the Ministry of Science and Technology of Vietnam. This is the top quality standard that is being applied by laboratories all over the world.
Attending the ceremony were representatives of the Bureau of Accreditation: Ms. Tran Thi Thu Ha - Director of BoA and Ms. Quach Hoang Lan - General Administration Department of BoA. On the side of GENTIS, there were Mr. Do Manh Ha (General Director of GENTIS), Colonel Ha Quoc Khanh (Former Director of the DNA Testing Center - Institute of Criminal Sciences; Former Deputy Director of the Institute of Criminal Sciences - Ministry of Public Security; Senior Scientific Advisor of GENTIS), Mr. Nguyen Quang Vinh (Director of GENTIS Laboratory Center) and managers,...
Mr. Do Manh Ha - General Director of GENTIS received the ISO 15189:2012 accreditation certificate from Ms. Tran Thi Thu Ha - Director of the Bureau of Accreditation (BoA)
In the medical field, the quality of tests plays a crucial role in helping doctors screen, diagnose and provide the most effective treatment for patients. Accurate testing helps doctors diagnose and treat the correct disease, help patients save costs and shorten treatment time and take the right drugs. This further motivates laboratories to develop quality management systems and improve their capacity and techniques to meet ISO 15189:2012 standards.
The event of GENTIS receiving the Certificate of Accreditation continues to maintain ISO 15189:2012 for GenEva services and expands ISO 15189:2012 for 3 services: NIPT, PGT A, Thalassemia Neonatal Screening once again affirms the quality of safe and effective testing services for Vietnamese citizens.
ISO 15189:2012 is a system that guides the control of all 3 stages before, during and after of the testing process and issues related to testing, bringing officials to perform quality control tests complying to a mandatory procedure. The application of ISO 15189:2012 standard is a reliable basis to help doctors when offering the most appropriate and effective treatment method for patients.
It’s such an honor for GENTIS to receive the Accreditation Certificate of maintaining ISO 15189:2012 for GenEva service and Accreditation Certificate of expanding ISO for 3 services: NIPT, PGT A, Neonatal screening of Thalassemia
In addition, the application of ISO 15189:2012 standards also helps test processes to be standardized, implemented synchronously, consistently, scientifically and correctly from the starting point to ensure quality. Moreover, it promotes strictly fulfilling the commitment of safe sample taking, returning results as soon as possible and keeping customer information confidential.
To achieve ISO 15189:2012, GENTIS must meet a lot of requirements in terms of management capacity, equipment, personnel competence and process compliance.... This is a testament to the reliability of the GenEva, NIPT, PGT A and Thalassemia Neonatal Screening tests at GENTIS. The ISO 15189:2012 Accreditation Certificate is the result of the efforts of the staff of GENTIS testing center and related departments on the way to standardize the testing system. Not only that, GENTIS also focuses on building a quality assurance management and inspection system through internal and external inspection programs.
Speaking at the opening ceremony, Ms. Tran Thi Thu Ha - Bureau of Accreditation (BoA) said: "ISO 15189:2012 accreditation is a process of striving and efforts of Genetic Analysis Services Joint Stock Company. However, maintaining accreditation also requires the Company to continue to make further efforts to maintain its capacity, techniques, as well as maintain the quality system. Not only maintaining, we also hope that the Company will continue to expand testing criteria to better serve patients and improve the quality of the company's services.
ISO 15189:2012 Accreditation Certificate is the motivation for GENTIS to make more efforts in the process of quality improvement
Speaking at the ceremony, Mr. Do Manh Ha (General Director of GENTIS Company) shared: "The process of quality improvement is a non-stop development process, which must be continuously improved. On the path of development, GENTIS relentlessly improves to bring the best quality to tests, as well as bring the best values to customers and partners. GENTIS will continue to pursue and develop to achieve more certifications, not only ISO 15189:2012 for some existing products, but will do more products in the future. In addition, GENTIS will continue to pursue higher certifications."
Also at the ceremony, Colonel Ha Quoc Khanh (Former Director of the DNA Testing Center - Institute of Criminal Sciences; Former Deputy Director of the Institute of Criminal Sciences - Ministry of Public Security; Senior Scientific Advisor of GENTIS) shared: "Product value is evaluated by the standards that are recognized as the best. The GENTIS professional team will try its best to maintain the recognized standards and expand further to meet the development needs of society and the community."
Up to now, GENTIS has achieved ISO 15189:2012, ISO 9001:2015 and ISO 13485:2016 standards. This further confirms that GENTIS is a pioneer in the field of genetic analysis, with the desire to help customers enjoy the best and most professional testing services.
With this quality affirmation, GENTIS hopes that Vietnamese people can easily take advantage of the quality of high-tech testing. At the same time, GENTIS hopes to contribute more to people's health care in terms of convenient on-site sampling services through cooperation with doctors, clinics, centers, and hospitals across the country.
PRESS RELEASE
About GENTIS conducting free DNA testing to find relatives for
families whose members were killed in the fire of
a mini apartment in Khuong Ha
Genetic Analysis Services Joint Stock Company (GENTIS) would like to send the most sincere condolences to the victims and families in the mini apartment fire that occurred on September 12, 2023 in Khuong Ha. The tragic accident and the sudden death of a loved one have left families with irreparable pain and loss.
With the desire to alleviate some of the pain for those who stay, GENTIS would like to support the families of the victims to do free DNA testing to determine blood relations (fathers and children, mothers and children, grandchildren, grandmothers, brothers and sisters, maternal and paternal relatives, etc.) to find their relatives in case they cannot be identified due to fire.
This small support of GENTIS hopes to partly help families reduce their grief and quickly find relatives to bring back to their hometowns.
All information should be sent to Genetic Analysis Services Joint Stock Company (GENTIS) at the address 8th Floor, No. 249A Thuy Khue, Tay Ho, Hanoi; Hotline 1800 2010.
Once again, GENTIS would like to express its deepest condolences to the families of the victims.
Respect.
GENTIS - The Main Sponsor of the ACP 2023 Annual Scientific Conference
GENTIS is honored to be the Main Sponsor of the 2023 National Scientific Conference of the Vietnam Medical Genetics Association.
Understanding Thrombophilia and Recurrent Pregnancy Loss
-360x194.png)
3 commonly used preimplantation genetic analysis tests or PGTest
New Study on Confirming Congenital Metabolic Disorder Screening Method by GENTIS and the University of Public Health Published in the Vietnam Medical Journal
Genetic Counseling with Tran Thi Chi Mai, MD. PhD. on Screening Newborn for Hemoglobinopathy
GENTIS receives ISO 15189:2012 Certification for GenEva, NIPT, PGT A and SLSS Thalassemia services
GENTIS provides free DNA testing to identify people, helping family members find relatives who were killed in the fire and were not identified
Quý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
Xem Socolive trực tuyến tiếng Việt
Link Bóng Đá Lu miễn phí
Link Rakhoi TV bóng đá trực tuyến
Xem tructiep https://xoilaczll.tv/
Link trực tiếp MitomTV bình luận tiếng Việt https://f8betht.baby Xem tructiep https://uniscore.com/vi NEW88 NEW88 789BET 789BET 789BETQuý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
